Ultra-Long-Term Delivery of Hydrophilic Drugs Using Injectable In Situ Cross-Linked Depots
Sohyung Lee,Spencer Zhao,Weihua Jiang,Xinyang Chen,Lingyun Zhu,John Joseph,Eli Agus,Helna Baby Mary,Shumaim Barooj,Kai Slaughter,Krisco Cheung,James N Luo,Chetan Shukla,Jingjing Gao,Dongtak Lee,Biji Balakrishnan,Christopher Jiang,Amogh Gorantla,Purna Shah,Sukyung Woo,Jeffrey Karp,Nitin Joshi
DOI: https://doi.org/10.1101/2023.11.04.565631
2024-08-28
Abstract:Achieving ultra-long-term release of hydrophilic drugs over several months remains a significant challenge for existing long-acting injectables (LAIs). Existing platforms, such as in situ forming implants (ISFI), exhibit high burst release due to solvent efflux and microsphere-based approaches lead to rapid drug diffusion due to significant water exchange and large pores. Addressing these challenges, we have developed an injectable platform that, for the first time, achieves ultra-long-term release of hydrophilic drugs for over six months. This system employs a methacrylated ultra-low molecular weight pre-polymer (polycaprolactone) to create in situ cross-linked depots (ISCD). The solvent-free design and dense mesh network of ISCD, both attributed to the ultra-low molecular weight of the pre-polymer, effectively minimizes burst release and water influx/efflux. In vivo studies in rats demonstrate that ISCD outperforms ISFI by achieving lower burst release and prolonged drug release. We demonstrated the versatility of ISCD by showcasing ultra-long-term delivery of several hydrophilic drugs, including antiretrovirals (tenofovir alafenamide, emtricitabine, abacavir, and lamivudine), antibiotics (vancomycin and amoxicillin) and an opioid antagonist naltrexone. Additionally, ISCD achieved ultra-long-term release of the hydrophobic drug tacrolimus and enabled co-delivery of hydrophilic drug combinations encapsulated in a single depot. We also identified design parameters to tailor the polymer network, tuning drug release kinetics and ISCD degradation. Pharmacokinetic modeling predicted over six months of drug release in humans, significantly surpassing the one-month standard achievable for hydrophilic drugs with existing LAIs. The biodegradability, retrievability, and biocompatibility of the platform further underscore its potential for improving treatment adherence in chronic conditions.
Bioengineering